Back to search results

Comparing Antibiotic Strategies for Children with Pneumonia (STAMPP)

This study, called STAMPP, is comparing two ways to give antibiotics to children aged 12 months to 71 months who have community-acquired pneumonia (a lung infection caught outside of a hospital). One group of children will get an antibiotic prescription to fill right away. The other group will get a "safety net" prescription, meaning parents will only give the antibiotic if the child doesn't improve or gets worse within 72 hours. The goal is to see if the "safety net" approach can reduce unnecessary antibiotic use while still helping children get better. We'll measure how well children improve and how much antibiotic is used over 7 days. This study is currently recruiting up to 2000 participants.

Study design
This is a randomized clinical trial, meaning participants are randomly assigned to one of two groups. The study plans to enroll up to 2000 children.
What's involved
You would complete online surveys on days 4 and 14, and receive a phone call on day 7 to collect information about your child's health.
Compensation
Not stated in the trial record.
Follow-up
Your child's clinical improvement and antibiotic use will be measured up to day 7 after enrollment. You will also complete surveys on days 4 and 14.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06986148

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

Recruiting
NAAges 12–71Interventional
Ann & Robert H Lurie Children's Hospital of Chicago
~2,000 participants
Updated 2026-01-27 on ClinicalTrials.gov
What's tested:Immediate Antibiotic Prescribing Group InstructionsSafety Net Antibiotic Prescribing (SNAP) Group Instructions

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinical Improvement
Measured over From enrollment to day 7
+1 more outcome measured

Conditions

Community Acquired Pneumonia (CAP)
Community Acquired Pneumonia

Explore related trials

Community-Acquired Pneumonia

Where it's being run

4 sites across 4 states
Georgia1
Illinois1
Pennsylvania1
Utah1

Study leadership

  • Todd Florin, MD, MSCE · PRINCIPAL_INVESTIGATOR · Ann & Robert H Lurie Children's Hospital of Chicago
  • Julia Szymczak, PhD · PRINCIPAL_INVESTIGATOR · University of Utah

Who to contact

Todd Florin, MD, MSCE
[email protected]
312-227-6675
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Aims 1 and 2:
Presenting with signs and symptoms of lower respiratory tract infection
Diagnosed with community-acquired pneumonia (CAP) by a clinician
The treating clinician intends to prescribe antibiotics for CAP, AND
Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.
Aim 3:
Parent/guardian of child enrolled in the trial, OR
Clinician who makes prescribing decision at the study site, OR
Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.

Exclusion

Aims 1 and 2:
Hospitalization within the previous 7 days
Oxygen saturation below 90%, if measured
Incomplete immunization status (e.g., lacking at least 3 doses of the pneumococcal vaccines, typically given as part of the 2-, 4-, and 6-month vaccinations)
Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),
Substantially immunocompromised status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)
Receipt of oral or parenteral antibiotics within the previous 7 days
Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)
Known bacterial source of infection warranting immediate antibiotics
Pneumonia diagnosis within the previous 6 months, OR
Prior enrollment in the trial
Inability of the parent or guardian to speak English or Spanish
Aim 3:
Inability of the parent or guardian to speak English

What this trial measures

  • Clinical ImprovementFrom enrollment to day 7

    Clinical improvement at 7 days after the index visit, defined as parent-reported (a) perception of overall improvement, (b) no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, (c) no new antibiotic use or hospitalization following the index visit, and (d) improvement in at least one key pneumonia symptom in (b).

  • Antibiotic UseFrom enrollment to day 7

    Antibiotic use through 7 days after the index visit, defined as Parent-reported antibiotic use (yes/no) at 7 days.